Improvement of Blood Plasmalogens and Clinical Symptoms in Parkinson’s Disease by Oral Administration of Ether Phospholipids: A Preliminary Report

Table 5

Improvement of clinical symptoms of Parkinson’s disease after oral administration of scallop-derived ether phospholipids.

PDQ-39	Before (n = 10), mean scores	After 24 weeks (n = 10), mean scores	value
Total	273.5 (145.2)	188.8 (93.8)	0.02
Mobility	50.5 (29.0)	48.8 (22.9)	0.66
Daily activity	48.8 (23.7)	35.4 (16.3)	0.05
Emotional well-being	40.4 (27.5)	26.3 (19.1)	0.07
Stigma	23.1 (17.9)	15.0 (17.7)	0.05
Social support	17.5 (18.2)	6.7 (12.3)	0.03
Cognitions	40.7 (19.8)	25.0 (16.4)	0.02
Communication	35.8 (33.8)	22.5 (26.4)	0.07
Bodily discomfort	16.7 (11.1)	9.2 (10.0)	0.03

Values are mean (SD) unless otherwise specified. Differences from before trial.